About Novogyne |
 |
|
Novogyne Pharmaceuticals is a joint venture between
Novartis Pharmaceuticals Corporation, and Noven Pharmaceuticals,
Inc. Since
May 1998, Novogyne has been offering pharmaceutical products that enable
physicians to better serve the medical needs of mature women. Novogyne's
products include Vivelle-Dot, the smallest estrogen patch available, Vivelle®
(estradiol transdermal system) and CombiPatch® (estradiol/norethindrone acetate
transdermal system). With these advanced patches, Novogyne was the first
company in the U.S. offering transdermal systems for both the estrogen-only and
combination estrogen/progestin markets.
What Do We Offer You?
With the mature woman’s comfort in mind, Novogyne offers the most advanced, and
wearable, transdermal patches on the market:
Vivelle-Dot, a postage-stamp-sized advanced generation estrogen patch and the
smallest estrogen patch available; and Vivelle (estradiol transdermal system),
a half-dollar-sized estrogen patch based on earlier adhesive matrix patch
technology.
CombiPatch (estradiol/norethindrone acetate transdermal system), the first
combination estrogen/progestin hormone therapy (HT) patch in the U.S.
The Novogyne Advantage
Novogyne’s systems deliver drugs utilizing an adhesive patch containing
medication. When adhered to the skin, medication is delivered through the
tissues and into the bloodstream over an extended period of time. Most of
Novogyne’s patches utilize the patented DOT Matrix™ technology, which allows
them to deliver more drug through a smaller patch area than any HT patches. DOT
Matrix achieves this without compromising the patch’s ability to adhere. DOT
Matrix patches adhere through normal activities, including showering, swimming
and exercise.
For more information on the DOT Matrix technology, click here.
DOT Matrix™ is a registered trademark of Noven Pharmaceuticals, Inc.
|
|
|
|